{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:57:41Z","timestamp":1770821861386,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10096-023-04704-8","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:14:22Z","timestamp":1700201662000},"page":"17-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1533-441X","authenticated-orcid":false,"given":"Roberta Maria","family":"Antonello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Saderi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"4704_CR1","unstructured":"World Health Organization. Antimicrobial resistance.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance"},{"key":"4704_CR2","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2147\/IDR.S206084","volume":"12","author":"SM Jabbari Shiadeh","year":"2019","unstructured":"Jabbari Shiadeh SM, Pormohammad A, Hashemi A, Lak P (2019) Global prevalence of antibiotic resistance in blood-isolated Enterococcus faecalis and Enterococcus faecium: a systematic review and meta-analysis. Infect Drug Resist 12:2713\u20132725. https:\/\/doi.org\/10.2147\/IDR.S206084","journal-title":"Infect Drug Resist"},{"key":"4704_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/mdr.2020.0147","volume":"27","author":"J Monticelli","year":"2021","unstructured":"Monticelli J, Di Bella S, Giacobbe DR et al (2021) Trends in the incidence and antibiotic resistance of enterococcal bloodstream isolates: a 7-year retrospective multicenter epidemiological study in Italy. Microb Drug Resist 27:529\u2013535. https:\/\/doi.org\/10.1089\/mdr.2020.0147","journal-title":"Microb Drug Resist"},{"key":"4704_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2022.11.017","volume":"132","author":"E Chang","year":"2023","unstructured":"Chang E, Im D, Lee HY et al (2023) Impact of discontinuing isolation in a private room for patients infected or colonized with vancomycin-resistant enterococci (VRE) on the incidence of healthcare-associated VRE bacteraemia in a hospital with a predominantly shared-room setting. J Hosp Infect 132:1\u20137. https:\/\/doi.org\/10.1016\/j.jhin.2022.11.017","journal-title":"J Hosp Infect"},{"issue":"12","key":"4704_CR5","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/jac\/dkw312","volume":"71","author":"AR Freitas","year":"2016","unstructured":"Freitas AR, Tedim AP, Francia MV et al (2016) Multilevel population genetic analysis of vanA and vanB Enterococcus faecium causing nosocomial outbreaks in 27 countries (1986\u20132012). J Antimicrob Chemother 71(12):3351\u20133366. https:\/\/doi.org\/10.1093\/jac\/dkw312","journal-title":"J Antimicrob Chemother"},{"key":"4704_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mib.2017.11.030","volume":"41","author":"W Gao","year":"2018","unstructured":"Gao W, Howden BP, Stinear TP (2018) Evolution of virulence in Enterococcus faecium, a hospital-adapted opportunistic pathogen. Curr Opin Microbiol 41:76\u201382. https:\/\/doi.org\/10.1016\/j.mib.2017.11.030","journal-title":"Curr Opin Microbiol"},{"key":"4704_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drup.2018.10.002","volume":"40","author":"JK Bender","year":"2018","unstructured":"Bender JK, Cattoir V, Hegstad K et al (2018) Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Updat 40:25\u201339. https:\/\/doi.org\/10.1016\/j.drup.2018.10.002","journal-title":"Drug Resist Updat"},{"key":"4704_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jiac.2018.01.001","volume":"24","author":"J Monticelli","year":"2018","unstructured":"Monticelli J, Knezevich A, Luzzati R, Di Bella S (2018) Clinical management of non-faecium non-faecalis vancomycin-resistant enterococci infection. Focus on Enterococcus gallinarum and Enterococcus casseliflavus\/flavescens. J Infect Chemother 24:237\u2013246. https:\/\/doi.org\/10.1016\/j.jiac.2018.01.001","journal-title":"J Infect Chemother"},{"key":"4704_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1128\/JCM.44.3.1153-1155.2006","volume":"44","author":"MG Bonora","year":"2006","unstructured":"Bonora MG, Solbiati M, Stepan E et al (2006) Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44:1153\u20131155. https:\/\/doi.org\/10.1128\/JCM.44.3.1153-1155.2006","journal-title":"J Clin Microbiol"},{"key":"4704_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jgar.2017.10.018","volume":"13","author":"R Bi","year":"2018","unstructured":"Bi R, Qin T, Fan W, Ma P, Gu B (2018) The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist 13:11\u201319. https:\/\/doi.org\/10.1016\/j.jgar.2017.10.018","journal-title":"J Glob Antimicrob Resist"},{"key":"4704_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/clinids\/9.6.1065","volume":"9","author":"SD Holmberg","year":"1987","unstructured":"Holmberg SD, Solomon SL, Blake PA (1987) Health and economic impacts of antimicrobial resistance. Rev Infect Dis 9:1065\u20131078. https:\/\/doi.org\/10.1093\/clinids\/9.6.1065","journal-title":"Rev Infect Dis"},{"key":"4704_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/clinids\/23.6.1234","volume":"23","author":"MB Edmond","year":"1996","unstructured":"Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP (1996) Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 23:1234\u20131239. https:\/\/doi.org\/10.1093\/clinids\/23.6.1234","journal-title":"Clin Infect Dis"},{"key":"4704_CR13","first-page":"260","volume":"45","author":"N Riccardi","year":"2022","unstructured":"Riccardi N, Antonello RM, Giacomelli A et al (2022) The challenge of infectious diseases consultations in the emergency department: an Italian nationwide survey. New Microbiol 45:260\u2013268","journal-title":"New Microbiol"},{"key":"4704_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10096-019-03801-x","volume":"39","author":"H Chen","year":"2020","unstructured":"Chen H, Du Y, Xia Q, Li Y, Song S, Huang X (2020) Role of linezolid combination therapy for serious infections: review of the current evidence. Eur J Clin Microbiol Infect Dis 39:1043\u20131052. https:\/\/doi.org\/10.1007\/s10096-019-03801-x","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4704_CR15","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1128\/AAC.00714-13","volume":"57","author":"DW Whang","year":"2013","unstructured":"Whang DW, Miller LG, Partain NM, McKinnell JA (2013) Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 57:5013\u20135018. https:\/\/doi.org\/10.1128\/AAC.00714-13","journal-title":"Antimicrob Agents Chemother"},{"key":"4704_CR16","doi-asserted-by":"publisher","first-page":"e003912","DOI":"10.1136\/bmjopen-2013-003912","volume":"3","author":"AC Kalil","year":"2013","unstructured":"Kalil AC, Klompas M, Haynatzki G, Rupp ME (2013) Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 3:e003912. https:\/\/doi.org\/10.1136\/bmjopen-2013-003912","journal-title":"BMJ Open"},{"key":"4704_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clinthera.2010.01.019","volume":"32","author":"E Chiappini","year":"2010","unstructured":"Chiappini E, Conti C, Galli L, de Martino M (2010) Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 32:66\u201388. https:\/\/doi.org\/10.1016\/j.clinthera.2010.01.019","journal-title":"Clin Ther"},{"key":"4704_CR18","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1093\/jac\/dkr285","volume":"66","author":"S Garazzino","year":"2011","unstructured":"Garazzino S, Krzysztofiak A, Esposito S et al (2011) Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 66:2393\u20132397. https:\/\/doi.org\/10.1093\/jac\/dkr285","journal-title":"J Antimicrob Chemother"},{"key":"4704_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12519-022-00650-1","volume":"19","author":"Y Shi","year":"2023","unstructured":"Shi Y, Wu H-L, Wu Y-H et al (2023) Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis. World J Pediatr 19:129\u2013138. https:\/\/doi.org\/10.1007\/s12519-022-00650-1","journal-title":"World J Pediatr"},{"key":"4704_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/mdr.2020.0171","volume":"27","author":"N Riccardi","year":"2021","unstructured":"Riccardi N, Monticelli J, Antonello RM et al (2021) Therapeutic options for infections due to vanB genotype vancomycin-resistant enterococci. Microb Drug Resist 27:536\u2013545. https:\/\/doi.org\/10.1089\/mdr.2020.0171","journal-title":"Microb Drug Resist"},{"key":"4704_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4704_CR22","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1128\/AAC.47.6.1902-1906.2003","volume":"47","author":"MT Sweeney","year":"2003","unstructured":"Sweeney MT, Zurenko GE (2003) In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 47:1902\u20131906. https:\/\/doi.org\/10.1128\/AAC.47.6.1902-1906.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"4704_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.diagnmicrobio.2018.07.015","volume":"93","author":"F Campanile","year":"2019","unstructured":"Campanile F, Bongiorno D, Mongelli G, Zangh\u00ec G, Stefani S (2019) Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates. Diagn Microbiol Infect Dis 93:77\u201381. https:\/\/doi.org\/10.1016\/j.diagnmicrobio.2018.07.015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"57","key":"4704_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000330458","volume":"26","author":"C Farina","year":"2011","unstructured":"Farina C, Russello G, Chinello P et al (2011) In vitro activity effects of twelve antibiotics alone and in association against twenty-seven Enterococcus faecalis strains isolated from Italian patients with infective endocarditis: high in vitro synergistic effect of the association ceftriaxone-fosfomycin. Chemotherapy 26(57):426\u2013433. https:\/\/doi.org\/10.1159\/000330458","journal-title":"Chemotherapy"},{"key":"4704_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10354-017-0603-1","volume":"169","author":"M Beitdaghar","year":"2019","unstructured":"Beitdaghar M, Ahmadrajabi R, Karmostaji A, Saffari F (2019) In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates. Wien Med Wochenschr 169:215\u2013221. https:\/\/doi.org\/10.1007\/s10354-017-0603-1","journal-title":"Wien Med Wochenschr"},{"key":"4704_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jinf.2005.05.022","volume":"52","author":"DW Wareham","year":"2006","unstructured":"Wareham DW, Abbas H, Karcher AM, Das SS (2006) Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 52:300\u2013304. https:\/\/doi.org\/10.1016\/j.jinf.2005.05.022","journal-title":"J Infect"},{"key":"4704_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5336\/medsci.2008-8693","volume":"30","author":"S Ermertcan","year":"2010","unstructured":"Ermertcan S, Hosg\u00f6r-Limoncu M, Tasli H, \u00c7illi F, Cosar G (2010) In vitro activity of linezolid in combination with vancomycin, teicoplanin, fusidic acid, and ciprofloxacin against gram-positive pathogens. Turkiye Klinikleri J Med Sci 30:59\u201364. https:\/\/doi.org\/10.5336\/medsci.2008-8693","journal-title":"Turkiye Klinikleri J Med Sci"},{"key":"4704_CR28","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/jac\/dkz010","volume":"74","author":"T Wu","year":"2019","unstructured":"Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E (2019) In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. J Antimicrob Chemother 74:1300\u20131305. https:\/\/doi.org\/10.1093\/jac\/dkz010","journal-title":"J Antimicrob Chemother"},{"key":"4704_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1556\/AMicr.58.2011.3.5","volume":"58","author":"M Aligholi","year":"2011","unstructured":"Aligholi M, Emaneini M, Taherikalani M et al (2011) Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium. Acta Microbiol Immunol Hung 58:219\u2013226. https:\/\/doi.org\/10.1556\/AMicr.58.2011.3.5","journal-title":"Acta Microbiol Immunol Hung"},{"key":"4704_CR30","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1128\/AAC.02790-13","volume":"58","author":"MK Luther","year":"2014","unstructured":"Luther MK, Arvanitis M, Mylonakis E, LaPlante KL (2014) Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother 58:4612\u20134620. https:\/\/doi.org\/10.1128\/AAC.02790-13","journal-title":"Antimicrob Agents Chemother"},{"key":"4704_CR31","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.2147\/DDDT.S315061","volume":"15","author":"J Tong","year":"2021","unstructured":"Tong J, Jiang Y, Xu H et al (2021) In vitro antimicrobial activity of fosfomycin, rifampin, vancomycin, daptomycin alone and in combination against vancomycin-resistant enterococci. Drug Des Devel Ther 15:3049\u20133055. https:\/\/doi.org\/10.2147\/DDDT.S315061","journal-title":"Drug Des Devel Ther"},{"key":"4704_CR32","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1128\/AAC.02099-12","volume":"57","author":"JL Descourouez","year":"2013","unstructured":"Descourouez JL, Jorgenson MR, Wergin JE, Rose WE (2013) Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 57:1518\u20131520. https:\/\/doi.org\/10.1128\/AAC.02099-12","journal-title":"Antimicrob Agents Chemother"},{"key":"4704_CR33","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.2147\/IDR.S219117","volume":"12","author":"C Qi","year":"2019","unstructured":"Qi C, Xu S, Wu M et al (2019) pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and -resistant enterococci in vitro and in vivo of a Galleria mellonella larval infection model. Infect Drug Resist 12:3497\u20133505. https:\/\/doi.org\/10.2147\/IDR.S219117","journal-title":"Infect Drug Resist"},{"key":"4704_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.diagnmicrobio.2013.07.012","volume":"77","author":"H-J Tang","year":"2013","unstructured":"Tang H-J, Chen C-C, Zhang C-C et al (2013) In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagn Microbiol Infect Dis 77:254\u2013257. https:\/\/doi.org\/10.1016\/j.diagnmicrobio.2013.07.012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4704_CR35","doi-asserted-by":"publisher","first-page":"605962","DOI":"10.3389\/fmicb.2020.605962","volume":"11","author":"L Jiang","year":"2020","unstructured":"Jiang L, Xie N, Chen M et al (2020) Synergistic combination of linezolid and fosfomycin closing each other\u2019s mutant selection window to prevent enterococcal resistance. Front Microbiol 11:605962. https:\/\/doi.org\/10.3389\/fmicb.2020.605962","journal-title":"Front Microbiol"},{"key":"4704_CR36","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2147\/IDR.S208298","volume":"12","author":"J Hemapanpairoa","year":"2019","unstructured":"Hemapanpairoa J, Changpradub D, Thunyaharn S, Santimaleeworagun W (2019) Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect. Infect Drug Resist 12:2049\u20132057. https:\/\/doi.org\/10.2147\/IDR.S208298","journal-title":"Infect Drug Resist"},{"key":"4704_CR37","doi-asserted-by":"publisher","first-page":"779885","DOI":"10.3389\/fmicb.2021.779885","volume":"12","author":"S Wang","year":"2021","unstructured":"Wang S, Liu H, Mao J et al (2021) pharmacodynamics of linezolid plus fosfomycin against vancomycin\u2013resistant Enterococcus faecium in a hollow fiber infection model. Front Microbiol 12:779885. https:\/\/doi.org\/10.3389\/fmicb.2021.779885","journal-title":"Front Microbiol"},{"key":"4704_CR38","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.2147\/IDR.S377848","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Peng Y, Zhang N et al (2022) Assessing the emergence of resistance in vitro and in vivo: linezolid combined with fosfomycin against fosfomycin-sensitive and resistant Enterococcus. Infect Drug Resist 15:4995\u20135010. https:\/\/doi.org\/10.2147\/IDR.S377848","journal-title":"Infect Drug Resist"},{"key":"4704_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21037\/atm-21-4595","volume":"10","author":"Y Yan","year":"2022","unstructured":"Yan Y, Yang G, Li Y et al (2022) Factorial design and post-antibiotic sub-MIC effects of linezolid combined with fosfomycin against vancomycin-resistant enterococci. Ann Transl Med 10:148. https:\/\/doi.org\/10.21037\/atm-21-4595","journal-title":"Ann Transl Med"},{"key":"4704_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijantimicag.2014.03.008","volume":"44","author":"A Holmberg","year":"2014","unstructured":"Holmberg A, Rasmussen M (2014) Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms. Int J Antimicrob Agents 44:78\u201380. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.008","journal-title":"Int J Antimicrob Agents"},{"key":"4704_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jac\/dkr477","volume":"67","author":"A Holmberg","year":"2012","unstructured":"Holmberg A, M\u00f6rgelin M, Rasmussen M (2012) Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J Antimicrob Chemother 67:433\u2013439. https:\/\/doi.org\/10.1093\/jac\/dkr477","journal-title":"J Antimicrob Chemother"},{"key":"4704_CR42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ijantimicag.2016.12.006","volume":"49","author":"K Skinner","year":"2017","unstructured":"Skinner K, Sandoe JAT, Rajendran R, Ramage G, Lang S (2017) Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model. Int J Antimicrob Agents 49:507\u2013511. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.006","journal-title":"Int J Antimicrob Agents"},{"key":"4704_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jgar.2014.09.004","volume":"2","author":"JM Entenza","year":"2014","unstructured":"Entenza JM, Giddey M, Vouillamoz J, Moreillon P, Mancini S (2014) Assessment of the in vitro synergy of daptomycin plus linezolid against multidrug-resistant enterococci. J Glob Antimicrob Resist 2:306\u2013308. https:\/\/doi.org\/10.1016\/j.jgar.2014.09.004","journal-title":"J Glob Antimicrob Resist"},{"key":"4704_CR44","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1128\/AAC.46.8.2606-2612.2002","volume":"46","author":"GP Allen","year":"2002","unstructured":"Allen GP, Cha R, Rybak MJ (2002) In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 46:2606\u20132612. https:\/\/doi.org\/10.1128\/AAC.46.8.2606-2612.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"4704_CR45","doi-asserted-by":"publisher","first-page":"115241","DOI":"10.1016\/jdiagnmicrobio.2020.115241","volume":"99","author":"C Lagatolla","year":"2021","unstructured":"Lagatolla C, Milic J, Imperi F et al (2021) Synergistic activity of fosfomycin and chloramphenicol against vancomycin-resistant Enterococcus faecium (VREfm) isolates from bloodstream infections. Diagn Microbiol Infect Dis 99:115241. https:\/\/doi.org\/10.1016\/jdiagnmicrobio.2020.115241","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4704_CR46","doi-asserted-by":"publisher","unstructured":"Antonello RM, Principe L, Maraolo AE et al (2020) Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics (Basel) 9(8):500. https:\/\/doi.org\/10.3390\/antibiotics9080500","DOI":"10.3390\/antibiotics9080500"},{"key":"4704_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/jac\/dkac346","volume":"78","author":"RM Antonello","year":"2022","unstructured":"Antonello RM, Canetti D, Riccardi N (2022) Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review. J Antimicrob Chemother 78:52\u201377. https:\/\/doi.org\/10.1093\/jac\/dkac346","journal-title":"J Antimicrob Chemother"},{"key":"4704_CR48","doi-asserted-by":"publisher","first-page":"e0214037","DOI":"10.1371\/journal.pone.0214037","volume":"14","author":"F Okazaki","year":"2019","unstructured":"Okazaki F, Tsuji Y, Seto Y, Ogami C, Yamamoto Y, To H (2019) Effects of a rifampicin pre-treatment on linezolid pharmacokinetics. PLoS ONE 14:e0214037. https:\/\/doi.org\/10.1371\/journal.pone.0214037","journal-title":"PLoS ONE"},{"key":"4704_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijantimicag.2019.04.010","volume":"54","author":"KA Meyer","year":"2019","unstructured":"Meyer KA, Deraedt MF, Harrington AT, Danziger LH, Wenzler E (2019) Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model. Int J Antimicrob Agents 54:197\u2013201. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.04.010","journal-title":"Int J Antimicrob Agents"},{"key":"4704_CR50","first-page":"853","volume":"86","author":"RJ Weinstein","year":"1975","unstructured":"Weinstein RJ, Young LS, Hewitt WL (1975) Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med 86:853\u2013862","journal-title":"J Lab Clin Med"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04704-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04704-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04704-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T12:09:44Z","timestamp":1704715784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04704-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["4704"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04704-8","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"17 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}